There is much incentive for Dr. Janet Woodcock & the FDA to be first to announce the approval of leronlimab. Remember, she was nominated as the INTERIM head of the FDA. She would be a lock for the permanent title if she were able to bring to market the first therapeutic that takes dying off the table. Very smart move on her part to request the data immediately upon unblinding.